...
search icon
grce-img

Grace Therapeutics, Inc., Common Stock

GRCE

NAQ

$2.669

-$0.36

(-11.88%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$39.71M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
57.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.37
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.13 L
$4.97 H
$2.669

About Grace Therapeutics, Inc., Common Stock

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. more

Returns

Data is not properly formatted.

Financials

Mar '21Mar '22Mar '23Mar '24
Total Revenue196.00K---[{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Cost of Revenue76.00K---[{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Gross Profit120.00K---[{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Gross Margin61.22%---[{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Operating Expenses10.91M15.34M18.25M11.37M[{"date":"2021-03-31","value":59.8,"profit":true},{"date":"2022-03-31","value":84.07,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":62.3,"profit":true}]
Operating Income(10.72M)(15.34M)(18.25M)(11.37M)[{"date":"2021-03-31","value":-1071600000,"profit":false},{"date":"2022-03-31","value":-1534000000,"profit":false},{"date":"2023-03-31","value":-1824700000,"profit":false},{"date":"2024-03-31","value":-1136700000,"profit":false}]
Total Non-Operating Income/Expense(8.96M)4.87M(33.72M)(3.32M)[{"date":"2021-03-31","value":-183.91,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-692.06,"profit":false},{"date":"2024-03-31","value":-68.09,"profit":false}]
Pre-Tax Income(19.68M)(10.47M)(51.97M)(14.69M)[{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-1046700000,"profit":false},{"date":"2023-03-31","value":-5197100000,"profit":false},{"date":"2024-03-31","value":-1468500000,"profit":false}]
Income Taxes----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Income From Continuous Operations(19.68M)(9.82M)(42.43M)(12.85M)[{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income(19.68M)(9.82M)(42.43M)(12.85M)[{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false}]
EPS (Diluted)(32.77)(1.58)(5.71)(1.54)[{"date":"2021-03-31","value":-3276.98,"profit":false},{"date":"2022-03-31","value":-157.94,"profit":false},{"date":"2023-03-31","value":-571.1,"profit":false},{"date":"2024-03-31","value":-153.88,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GRCE
Current Ratio 6.06

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GRCE
ROA (LTM) -15.16%
ROE (LTM) -22.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GRCE
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GRCE
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.62
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Grace Therapeutics, Inc. share price today?

Grace Therapeutics, Inc. (GRCE) share price today is $2.669

Can Indians buy Grace Therapeutics, Inc. shares?

Yes, Indians can buy shares of Grace Therapeutics, Inc. (GRCE) on Vested. To buy Grace Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GRCE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Grace Therapeutics, Inc. be purchased?

Yes, you can purchase fractional shares of Grace Therapeutics, Inc. (GRCE) via the Vested app. You can start investing in Grace Therapeutics, Inc. (GRCE) with a minimum investment of $1.

How to invest in Grace Therapeutics, Inc. shares from India?

You can invest in shares of Grace Therapeutics, Inc. (GRCE) via Vested in three simple steps:

  • Click on Sign Up or Invest in GRCE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Grace Therapeutics, Inc. shares
What is Grace Therapeutics, Inc. 52-week high and low stock price?

The 52-week high price of Grace Therapeutics, Inc. (GRCE) is $4.97. The 52-week low price of Grace Therapeutics, Inc. (GRCE) is $2.13.

What is Grace Therapeutics, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Grace Therapeutics, Inc. (GRCE) is 0.62

What is the Market Cap of Grace Therapeutics, Inc.?

The market capitalization of Grace Therapeutics, Inc. (GRCE) is $39.71M

What is Grace Therapeutics, Inc.’s stock symbol?

The stock symbol (or ticker) of Grace Therapeutics, Inc. is GRCE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top